Owkin has announced an agreement with Servier to license Owkin K Pro and multimodal patient data. The agreement will support Servier’s oncology research initiatives. Owkin operates as an agentic AI company focused on drug discovery and development. The company is developing an automated AI scientist for pharmaceutical research. Servier is an independent international pharmaceutical group governed by a foundation. Under the agreement, Servier’s research teams will access Owkin’s multimodal patient data.
The teams will analyze this data through K Pro, Owkin’s AI scientist. The platform combines patient information with specialized biological agentic AI. The latest agreement builds on an existing collaboration between Owkin and Servier. Their previous work focused on patient subgroup identification within oncology. The new collaboration expands the relationship toward broader AI-driven research capabilities. It also gives Servier access to advanced tools for investigating complex cancer biology.
K Pro brings multimodal patient data and biological AI capabilities into pharmaceutical workflows. Therefore, researchers can use the platform to support decision-making across different stages. The AI scientist applies specialized biological tools to pharmaceutical research challenges. Owkin developed these capabilities using knowledge gained from a decade of pharmaceutical partnerships.
The platform also incorporates findings from Owkin’s latest AI research. In addition, K Pro uses real-world patient data for training and validation. Owkin also validates K Pro through its wet lab capabilities. This approach helps connect computational analysis with biological research.
Thomas Clozel, CEO and co-founder of Owkin, described the importance of the agreement. “Our AI scientist is changing the way biopharma works,” said Thomas Clozel, CEO and co-founder of Owkin. “By pairing K Pro with Owkin’s multimodal patient data, Servier’s scientists can investigate the biology of hard-to-treat cancers and reach answers that manual analysis alone cannot deliver.”
K Pro Brings AI Capabilities Across Drug Development
K Pro supports a number of key activities along the pharmaceutical value chain. These capabilities include discovery of targets and optimization of molecules. The platform also supports biomarker identification and sub-group optimization. Also, it can assist in clinical trial design. These capabilities can allow researchers to explore complex biological questions more efficiently. They also enable faster decision-making in drug discovery and development.
K Pro combines different forms of patient information for deeper analysis. As a result, researchers can examine disease biology from multiple perspectives. This multimodal approach can support research involving difficult-to-treat cancers. It can also help teams investigate relationships that manual analysis may not reveal quickly.
The collaboration gives Servier’s researchers access to AI-driven analysis and patient data. Therefore, teams can explore research questions through a more connected workflow.
The agreement also reflects the increasing role of AI in pharmaceutical research. Biopharma companies continue to explore technologies that can improve research efficiency.
Servier Applies AI to Hard-to-Treat Cancer Research
Servier continues to seek new approaches for understanding disease biology. The company also focuses on developing better treatments for patients with difficult cancers. Claude Bertrand, Executive Vice President, Research & Development, Servier, highlighted the value of the collaboration.
“At Servier, we are constantly looking for new ways to deepen our understanding of disease biology and to bring better treatments to patients with hard-to-treat cancers. Access to high-quality patient data and AI-driven analysis in one place, through K Pro, helps our teams generate and test hypotheses with greater speed and confidence. We look forward to applying these capabilities across our oncology research,” said Claude Bertrand, Executive Vice President, Research & Development, Servier.
The agreement brings high-quality patient data together with AI-powered research capabilities. Consequently, Servier’s teams can generate and test research hypotheses more efficiently. The collaboration also strengthens the use of multimodal data in oncology research. Researchers can examine patient information through K Pro’s specialized AI capabilities. At the same time, Owkin continues to expand the role of AI across pharmaceutical research. Its platform combines data, biological tools, and AI analysis within one environment.
The Servier partnership is a further step in that strategy. It extends the companies’ prior oncology partnership in patient subgroup identification. The agreement gives Servier access to K Pro and Owkin’s multi-modal patient data. These resources can be applied to the company’s oncology research programs. The collaboration will assist in improving understanding of disease and make research more efficient. In the end, both companies are trying to press ahead with AI-led approaches in tough areas of cancer research.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
